Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477474 · ClinicalTrials.gov registry record
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
A clinical trial, sponsored by Guardant Health.
- Terminated
- Registry status
- 311
- Enrollment target
NCT03477474: Clinical Trial study, sponsored by Guardant Health.
NCT03477474 is a clinical trial that was terminated before completion, run by Guardant Health. The registered enrollment target is 311 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477474 was terminated before completion, sponsored by Guardant Health.
- TERMINATED
- Registry status
- 311 participants
- Enrollment target
Study Summary
The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2019-09-01 |
Why NCT03477474 stopped before completion
NCT03477474 is an observational study that tracks outcomes without assigning an intervention. The registered 311 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03477474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03477474 about?
NCT03477474 is a clinical study titled "Registry of Guardant360® Use and Outcomes In People With Advanced Cancer". The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
What is the current status of trial NCT03477474?
This trial is currently terminated. The enrollment target is 311 participants. The study started on 2018-04-06. Estimated completion is 2019-09-01.
Who is sponsoring clinical trial NCT03477474?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI